Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.20

-5.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2694)	1/26/2001 7:20:26 PM
From: Miljenko Zuanic	Read Replies (1) of 52153

Q: Why is 80% reduction -> p=NS? A: Maybe because the incidence is so low to begin with? Yes, Peter. This are my though. And I didn't liked when they combined mortality with Non-Q MI to show efficacy in subgroup. While combined MI as end-point failed. Why there is more Q-MI in drug group than in placebo (4.7% versus 3.3%). Side effects??? All this leave me with impression that second PII trial in acute MI may fail as well. Results, I exit my (small) ALXN position today. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next